Literature DB >> 22426015

Anticholinergic drugs in late life: adverse effects on cognition but not on progress to dementia.

Lawrence J Whalley1, Sumit Sharma, Helen C Fox, Alison D Murray, Roger T Staff, Ashleigh C Duthie, Ian J Deary, John M Starr.   

Abstract

Impaired cognitive function associated with use of anticholinergic drugs may be partly attributed to underlying physical illness and exposure to factors that increase the risk of some physical disorders such as low socioeconomic status (SES) and less education. To estimate the extent of cognitive impairment and risk of progress to dementia associated with anticholinergic drug use and to estimate confounding by gender, APOE, family history of dementia, lower SES, less education, and lower childhood mental ability, we recruited 281 volunteers at age 77-78 without overt dementia who had taken part in the Scottish Mental Survey of 1932. Clinical histories, use of medications, self reported frequency of emotional symptoms and standardized tests of cognitive function were obtained. With and without adjustment for age and childhood IQ, there were significant between-group differences in tests of non-verbal reasoning and spatial ability. During 10 year follow-up, progress to overt dementia was not associated with anticholinergic drugs use on recruitment but female gender and a history of dementia in parent or sibling were associated with dementia. We concluded that anticholinergic drug use in this narrow age range sample was linked to cognitive impairment but not to subsequent dementia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426015     DOI: 10.3233/JAD-2012-110935

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  18 in total

Review 1.  Anticholinergic medication use and dementia: latest evidence and clinical implications.

Authors:  Shelly L Gray; Joseph T Hanlon
Journal:  Ther Adv Drug Saf       Date:  2016-07-18

2.  Anticholinergic Drug Burden Tools/Scales and Adverse Outcomes in Different Clinical Settings: A Systematic Review of Reviews.

Authors:  Tomas J Welsh; Veronika van der Wardt; Grace Ojo; Adam L Gordon; John R F Gladman
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

Review 3.  Different methods, different results--how do available methods link a patient's anticholinergic load with adverse outcomes?

Authors:  Tanja Mayer; Walter E Haefeli; Hanna M Seidling
Journal:  Eur J Clin Pharmacol       Date:  2015-09-08       Impact factor: 2.953

4.  Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis.

Authors:  Kimberley Ruxton; Richard J Woodman; Arduino A Mangoni
Journal:  Br J Clin Pharmacol       Date:  2015-05-20       Impact factor: 4.335

5.  Size of the associations between anticholinergic burden tool scores and adverse outcomes in older patients.

Authors:  Marta Lavrador; Ana C Cabral; Isabel V Figueiredo; Manuel T Veríssimo; M Margarida Castel-Branco; Fernando Fernandez-Llimos
Journal:  Int J Clin Pharm       Date:  2020-08-29

Review 6.  Association between anticholinergic drug burden and mortality in older people: a systematic review.

Authors:  Sheraz Ali; Gregory M Peterson; Luke R Bereznicki; Mohammed S Salahudeen
Journal:  Eur J Clin Pharmacol       Date:  2019-12-12       Impact factor: 2.953

7.  Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study.

Authors:  Maximilian Burger; Dietmar Betz; Christian Hampel; Monika Vogel
Journal:  World J Urol       Date:  2013-10-18       Impact factor: 4.226

8.  Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome.

Authors:  Martin Taylor-Rowan; Sophie Edwards; Anna H Noel-Storr; Jenny McCleery; Phyo K Myint; Roy Soiza; Carrie Stewart; Yoon Kong Loke; Terry J Quinn
Journal:  Cochrane Database Syst Rev       Date:  2021-05-05

Review 9.  Dementia ascertainment using existing data in UK longitudinal and cohort studies: a systematic review of methodology.

Authors:  Ruth A Sibbett; Tom C Russ; Ian J Deary; John M Starr
Journal:  BMC Psychiatry       Date:  2017-07-03       Impact factor: 3.630

10.  An anticholinergic burden score for German prescribers: score development.

Authors:  Esther Katharina Kiesel; Yvonne Marina Hopf; Michael Drey
Journal:  BMC Geriatr       Date:  2018-10-11       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.